Friday, 10 January 2014

Global Fund Welcomes Nomination of Deborah Birx


The Global Fund to Fight AIDS, Tuberculosis and Malaria enthusiastically praised the nomination of Deborah Birx to be the next Global AIDS Coordinator for the United States, leading the President's Emergency Plan for AIDS Relief (PEPFAR) and managing the U.S. Government’s relationship with the Global Fund.
Dr. Birx, a distinguished public health expert, has served as Director of the Division of Global HIV/AIDS at the Center for Disease Control since 2005. Trained as a clinician in immunology, she has dedicated her life to changing the course of HIV/AIDS, with nearly two decades of international experience in Africa and Asia.
"Dr. Birx is a true leader in global health, and her rich experience makes her an exceptional choice,” said Dr. Nafsiah Mboi, Chair of the Board of the Global Fund. “We are very excited to work together with her in our common mission to defeat AIDS, TB and malaria.”
Mark Dybul, Executive Director of the Global Fund, added: “Debbi is absolutely outstanding. She is one of the best scientist-policy makers around, and she is also a great pleasure to work with. We look forward to doing great things together.”
Dr. Birx began her career as a clinician in pediatric and adult immunology, focusing on clinical HIV/AIDS, vaccine research and global health. She served as Assistant Chief of the Allergy Immunology Service at Walter Reed Army Medical Center, and earned the U.S. Meritorious Service Medal for her leadership in refining, validating, and standardizing cell-mediated immunity testing in HIV-infected patients.
During her military career, Dr. Birx brought together the Navy, Army, and Air Force in a new model of cooperation increasing the efficiency and effectiveness of the U.S. Military’s HIV/AIDS clinical and basic research.
Once confirmed, Dr. Birx will succeed Ambassador Eric Goosby, who was U.S. Global AIDS Coordinator between 2009 and 2013.

No comments:

Post a Comment

New data on twice-yearly lenacapavir for HIV prevention announced at HIVR4P 2024

  New data on twice-yearly lenacapavir for HIV prevention announced at HIVR4P 2024 By Hope Mafaranga  New data from the PURPOSE 2 study of ...